X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Insights

Morphogenesis announces USDA-sanctioned clinical trial for promising equine cancer vaccine

Yuvraj_pawp by Yuvraj_pawp
5th September 2014
in Insights

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Morphogenesis Inc., the biotechnology firm developing ImmuneFx™, a cancer vaccine that has improved the longevity and quality of life for dogs, cats and horses, announces that a formal equine clinical trial for the direct injection form of the vaccine will begin later this month at a large equine facility in Missouri.

 

Pat Lawman, PhD., co-founder and CEO of Morphogenesis Inc., said that melanoma is a problem in grey horses and can be slow-growing or malignant. There is currently no USDA-approved treatment for equine melanoma.

 

Expected to last about a year, the clinical trial is designed to precisely assess the efficacy and safety of the ImmuneFx™ cancer vaccine in horses.

 

“We have had some major successes in reducing equine melanoma in the cases we have treated to date, and depending on the results, this formal study will statistically and scientifically establish the reliability of the therapy,” said Dr. Lawman.

ImmuneFx™ has been used to treat more than 20 different types of cancers in dogs, cats and horses. In fact, the personalized form of ImmuneFx™ is currently being used by veterinarians across the U.S.

 

In this equine study, Kris Hennessy, Ph.D, DVM, of Hennessy Research, will be testing an off-the-shelf form of ImmuneFx™ vaccine that is directly injected into the melanoma lesions of the horses. Successful study outcomes will allow Morphogenesis to obtain a commercial license from the USDA to sell the injectable form of ImmuneFx™ for treatment of equine melanoma.

 

Plans call for the personalized form of ImmuneFx™ to be in human clinical trials early next year. All the company’s activities, including its clinical trials, are investor-funded.

 

ABOUT MORPHOGENESIS

 

Morphogenesis Inc. (www.morphogenesis-inc.com) is a privately-held biotechnology company that is conducting ground-breaking research in the rapidly growing cell therapy, biologics and tissue engineering fields. The company has received financial support from grantors and private investors around the world.

 

Morphogenesis holds more than 20 U.S. issued and pending patents that cover rare cell identification and separation technologies, stem cell growth factors and cancer vaccines. Morphogenesis is currently focused on its multi-indication therapeutic cancer vaccine, ImmuneFx™, which educates the patient’s own immune system to attack tumor cells throughout the body without damaging normal cells or systems.

 

ABOUT THE IMMUNOTHERAPY MARKET

 

Several leading authorities project the annual therapeutic cancer vaccine market to expand to $8 billion within the next six years. Immunotherapy revenues worldwide are predicted to reach $35 billion in 10 years. Experts predict that within the next 10 years, 50-60 percent of cancer treatments will involve immunotherapy.

SOURCE Morphogenesis Inc.

Previous Post

Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical

Next Post

Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Related Posts

wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
high volume injectable formulations
Insights

Overcoming Challenges in High-Volume Injectable Formulations

27th September 2025
Insights

Smart Drug Delivery Systems for Patient Care

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
active pharmaceutical ingredients supply chain
Drug Development

Future of Active Pharmaceutical Ingredients Supply

26th September 2025
pharmaceutical excipients for new therapies
Drug Development

Advances in Pharmaceutical Excipients for New Therapies

26th September 2025
Next Post

Phase Holographic Imaging Announces Collaboration Agreement with Northeastern University

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In